Q1 Earnings Forecast for ESPR Issued By HC Wainwright

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research note issued to investors on Tuesday, March 4th. HC Wainwright analyst J. Pantginis expects that the biopharmaceutical company will post earnings per share of ($0.16) for the quarter. HC Wainwright has a "Buy" rating and a $16.00 price objective on the stock. The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Esperion Therapeutics' Q2 2025 earnings at ($0.12) EPS and Q4 2025 earnings at ($0.01) EPS.

A number of other research analysts also recently issued reports on ESPR. StockNews.com downgraded shares of Esperion Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, November 15th. JMP Securities restated a "market outperform" rating and issued a $4.00 price objective (down from $7.00) on shares of Esperion Therapeutics in a report on Tuesday, February 11th. Needham & Company LLC reaffirmed a "buy" rating and set a $6.00 target price on shares of Esperion Therapeutics in a report on Friday, December 13th. Cantor Fitzgerald assumed coverage on shares of Esperion Therapeutics in a research report on Tuesday, December 17th. They set an "overweight" rating and a $8.00 target price for the company. Finally, The Goldman Sachs Group initiated coverage on Esperion Therapeutics in a research report on Wednesday, December 18th. They issued a "neutral" rating and a $4.00 price target on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $6.75.

Remove Ads

Esperion Therapeutics Trading Down 6.5 %

Shares of ESPR traded down $0.11 during trading hours on Thursday, hitting $1.58. 6,185,751 shares of the stock traded hands, compared to its average volume of 4,101,159. The business has a fifty day moving average of $1.96 and a 200-day moving average of $2.09. The firm has a market capitalization of $311.32 million, a PE ratio of -2.47 and a beta of 1.04. Esperion Therapeutics has a 1-year low of $1.56 and a 1-year high of $3.94.

Hedge Funds Weigh In On Esperion Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ESPR. Wasatch Advisors LP raised its stake in Esperion Therapeutics by 38.4% during the 3rd quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company's stock worth $38,521,000 after buying an additional 6,483,070 shares during the period. Nuveen Asset Management LLC raised its position in shares of Esperion Therapeutics by 48.6% during the fourth quarter. Nuveen Asset Management LLC now owns 3,119,253 shares of the biopharmaceutical company's stock worth $6,862,000 after purchasing an additional 1,020,243 shares during the period. Bank of America Corp DE lifted its holdings in shares of Esperion Therapeutics by 45.1% during the 4th quarter. Bank of America Corp DE now owns 1,629,980 shares of the biopharmaceutical company's stock valued at $3,586,000 after purchasing an additional 506,428 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Esperion Therapeutics by 18.6% in the 4th quarter. JPMorgan Chase & Co. now owns 2,454,216 shares of the biopharmaceutical company's stock valued at $5,399,000 after purchasing an additional 385,099 shares during the period. Finally, Public Employees Retirement System of Ohio bought a new stake in Esperion Therapeutics during the 3rd quarter worth approximately $606,000. Institutional investors and hedge funds own 47.39% of the company's stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.